Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden | Zendy

Thomas Davidson | Zendy; Magnus Husberg | Zendy; Magnus Janzon | Zendy; Jonas Oldgren | Zendy; LarsÅke Levin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden

Author(s) -

Thomas Davidson,

Magnus Husberg,

Magnus Janzon,

Jonas Oldgren,

LarsÅke Levin

Publication year - 2012

Publication title -

european heart journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.336

H-Index - 293

eISSN - 1522-9645

pISSN - 0195-668X

DOI - 10.1093/eurheartj/ehs157

Subject(s) - dabigatran , medicine , warfarin , atrial fibrillation , stroke (engine) , vitamin k antagonist , quality adjusted life year , cost effectiveness , anesthesia , emergency medicine , intensive care medicine , mechanical engineering , risk analysis (engineering) , engineering

Patients with atrial fibrillation have a significantly increased risk of thromboembolic events such as ischaemic stroke, and patients are therefore recommended to be treated with anticoagulation treatment. The most commonly used anticoagulant consists of vitamin K antagonist such as warfarin. A new oral anticoagulation treatment, dabigatran, has recently been approved for stroke prevention among patients with atrial fibrillation. The purpose of this study was to estimate the cost-effectiveness of dabigatran as preventive treatment of stroke and thromboembolic events compared with warfarin in 65-year-old patients with atrial fibrillation in Sweden.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research